PRALUENT DIN 02547732
Status: Marketed
Holder: SANOFI-AVENTIS CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | ALIROCUMAB 300 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | C10AX14 ALIROCUMAB |
|---|
| Original market date | 16-Sep-2024 |
|---|
| Current status date | 16-Sep-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ALIROCUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02453819 | PRALUENT | SANOFI-AVENTIS CANADA INC | Solution | ALIROCUMAB 75 MG | Marketed |
| 02453835 | PRALUENT | SANOFI-AVENTIS CANADA INC | Solution | ALIROCUMAB 150 MG | Marketed |
| 02453754 | PRALUENT | SANOFI-AVENTIS CANADA INC | Solution | ALIROCUMAB 75 MG | Cancelled Post Market |
| 02453762 | PRALUENT | SANOFI-AVENTIS CANADA INC | Solution | ALIROCUMAB 150 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33250 | 2024-03-15 | Supplement to a New Drug Submission (SNDS) | New presentation |
Request a quote for PRALUENT
How to read a Canadian DIN record